These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 31655296)
1. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. Owonikoko TK; Niu H; Nackaerts K; Csoszi T; Ostoros G; Mark Z; Baik C; Joy AA; Chouaid C; Jaime JC; Kolek V; Majem M; Roubec J; Santos ES; Chiang AC; Speranza G; Belani CP; Chiappori A; Patel MR; Czebe K; Byers L; Bahamon B; Li C; Sheldon-Waniga E; Kong EF; Williams M; Badola S; Shin H; Bedford L; Ecsedy JA; Bryant M; Jones S; Simmons J; Leonard EJ; Ullmann CD; Spigel DR; J Thorac Oncol; 2020 Feb; 15(2):274-287. PubMed ID: 31655296 [TBL] [Abstract][Full Text] [Related]
2. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019 [TBL] [Abstract][Full Text] [Related]
3. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311 [TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658 [TBL] [Abstract][Full Text] [Related]
6. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Kubota K; Yoshioka H; Oshita F; Hida T; Yoh K; Hayashi H; Kato T; Kaneda H; Yamada K; Tanaka H; Ichinose Y; Park K; Cho EK; Lee KH; Lin CB; Yang JC; Hara K; Asato T; Nakagawa K J Clin Oncol; 2017 Nov; 35(32):3662-3670. PubMed ID: 28902534 [TBL] [Abstract][Full Text] [Related]
7. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
8. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294 [TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. O'Connor OA; Özcan M; Jacobsen ED; Roncero JM; Trotman J; Demeter J; Masszi T; Pereira J; Ramchandren R; Beaven A; Caballero D; Horwitz SM; Lennard A; Turgut M; Hamerschlak N; d'Amore FA; Foss F; Kim WS; Leonard JP; Zinzani PL; Chiattone CS; Hsi ED; Trümper L; Liu H; Sheldon-Waniga E; Ullmann CD; Venkatakrishnan K; Leonard EJ; Shustov AR; J Clin Oncol; 2019 Mar; 37(8):613-623. PubMed ID: 30707661 [TBL] [Abstract][Full Text] [Related]
10. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S; Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639 [TBL] [Abstract][Full Text] [Related]
11. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354 [TBL] [Abstract][Full Text] [Related]
12. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944 [TBL] [Abstract][Full Text] [Related]
14. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J; Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861 [TBL] [Abstract][Full Text] [Related]
15. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Kelly KR; Friedberg JW; Park SI; McDonagh K; Hayslip J; Persky D; Ruan J; Puvvada S; Rosen P; Iyer SP; Stefanovic A; Bernstein SH; Weitman S; Karnad A; Monohan G; VanderWalde A; Mena R; Schmelz M; Spier C; Groshen S; Venkatakrishnan K; Zhou X; Sheldon-Waniga E; Leonard EJ; Mahadevan D Clin Cancer Res; 2018 Dec; 24(24):6150-6159. PubMed ID: 30082475 [TBL] [Abstract][Full Text] [Related]
16. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675 [TBL] [Abstract][Full Text] [Related]
17. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322 [TBL] [Abstract][Full Text] [Related]
18. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786 [TBL] [Abstract][Full Text] [Related]
19. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592 [TBL] [Abstract][Full Text] [Related]
20. Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. Lim KH; Opyrchal M; Acharya A; Boice N; Wu N; Gao F; Webster J; Lockhart AC; Waqar SN; Govindan R; Morgensztern D; Picus J; Tan BR; Baggstrom MQ; Maher CA; Wang-Gillam A Eur J Cancer; 2021 Sep; 154():102-110. PubMed ID: 34256279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]